Lilly(US:LLY) ZACKSยท2025-07-29 22:46Company Overview - Eli Lilly (LLY) closed at $762.95, reflecting a -5.59% change from the previous day, which is worse than the S&P 500's daily loss of 0.3% [1] - Over the last month, Eli Lilly's shares increased by 3.67%, outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The upcoming earnings report for Eli Lilly is expected on August 7, 2025, with an anticipated EPS of $5.61, representing a 43.11% increase year-over-year [2] - Revenue is forecasted to be $14.75 billion, indicating a 30.49% growth compared to the same quarter of the previous year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $22.05 per share and revenue of $60.55 billion, reflecting increases of +69.75% and +34.43% respectively from the prior year [3] - Recent changes to analyst estimates for Eli Lilly are noted as indicators of optimism regarding the business outlook [3] Stock Performance and Valuation - The Zacks Rank system, which assesses estimate changes, indicates that Eli Lilly currently holds a Zacks Rank of 3 (Hold) [5] - The Zacks Consensus EPS estimate has increased by 0.48% in the past month [5] - Eli Lilly's Forward P/E ratio is 36.64, which is a premium compared to its industry's Forward P/E of 14.23 [5] Industry Context - Eli Lilly operates within the Large Cap Pharmaceuticals industry, which has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [7] - The average PEG ratio for the Large Cap Pharmaceuticals industry is 1.24, while Eli Lilly's PEG ratio is 1.15 [6]